source
- Vivoryon reclaims Chinese rights to kidney disease drug amid cash crunchVivoryon Therapeutics, a Munich-based biotech, has taken back the rights to develop its kidney disease candidate in China after a licensing arrangement with Simcere Pharmaceuticals. The original 2…
- Novo Nordisk lifts 2026 profit outlook after Wegovy obesity pill beats forecastsNovo Nordisk announced on Wednesday that it is raising its full-year profit and sales guidance after the third-quarter results for its Wegovy obesity pill came in above analysts' expectations. The…